

Electronic Medical Record Search Engine (EMERSE): An Information Retrieval Tool for Supporting Cancer Research

David A. Hanauer, MD, MS¹; Jill S. Barnholtz-Sloan, PhD^{2,4}; Mark F. Beno, MSM^{2,4}; Guilherme Del Fiol, MD, PhD⁵; Eric B. Durbin, DrPH^{6,7}; Oksana Gologorskaya, MS⁸; Daniel Harris, PhD^{6,7}; Brett Harnett, MSIS⁹; Kensaku Kawamoto, MD, PhD, MHS⁵; Benjamin May, MS¹⁰; Eric Meeks, BS⁸; Emily Pfaff, MS¹¹; Janie Weiss, BS¹⁰; and Kai Zheng, PhD¹²

PURPOSE The Electronic Medical Record Search Engine (EMERSE) is a software tool built to aid research spanning cohort discovery, population health, and data abstraction for clinical trials. EMERSE is now live at three academic medical centers, with additional sites currently working on implementation. In this report, we describe how EMERSE has been used to support cancer research based on a variety of metrics.

METHODS We identified peer-reviewed publications that used EMERSE through online searches as well as through direct e-mails to users based on audit logs. These logs were also used to summarize use at each of the three sites. Search terms for two of the sites were characterized using the natural language processing tool MetaMap to determine to which semantic types the terms could be mapped.

RESULTS We identified a total of 326 peer-reviewed publications that used EMERSE through August 2019, although this is likely an underestimation of the true total based on the use log analysis. Oncology-related research comprised nearly one third ($n = 105$; 32.2%) of all research output. The use logs showed that EMERSE had been used by multiple people at each site (nearly 3,500 across all three) who had collectively logged into the system $> 100,000$ times. Many user-entered search queries could not be mapped to a semantic type, but the most common semantic type for terms that did match was “disease or syndrome,” followed by “pharmacologic substance.”

CONCLUSION EMERSE has been shown to be a valuable tool for supporting cancer research. It has been successfully deployed at other sites, despite some implementation challenges unique to each deployment environment.

JCO Clin Cancer Inform 4:454-463. © 2020 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License 

INTRODUCTION

The vast volume of clinical data captured within electronic health records (EHRs) has the potential to catalyze biomedical research. However, for all the benefits of EHRs, persistent challenges remain in leveraging EHR data for cancer research. This is because a substantial number (up to 80% by some estimates)¹ of the clinical details are captured in unstructured free-text notes and are therefore difficult to extract and convert to a computable form.²

Ignoring the free text in EHRs can be problematic.³ For example, symptomatic data are often recorded exclusively in the free text.⁴ One study found that free text from EHRs was required for resolving nearly 60% of eligibility criteria for a chronic lymphocytic leukemia clinical trial and almost 80% of eligibility criteria for a prostate cancer trial.⁵ Another such study listed 10 data elements derived from the free text related to bone marrow biopsy findings, including biopsy blast

counts, biopsy cellularity, fibrosis grade, and aspirate cellularity.⁶ A study about engraftment syndrome after allogeneic hematopoietic cell transplantation used concepts found in the free text, such as engraftment failure, stool output, lymphocyte recovery, cytokine storm, disorientation, capillary leak, effusions, fevers, and rashes.⁷ Furthermore, the accuracy of the readily accessible structured data from EHRs may be low in some cases.⁸ For example, one study found that up to 20% of patients at one medical center had a medication listed in their unstructured data that was not in the structured medication list.⁹ Another study of cancer staging found that nearly 84% of patients had conflicting statements about staging in their records, necessitating an algorithm to infer the most likely staging for each patient.¹⁰

To help the research community use the free text in EHRs, substantial resources have been devoted to develop natural language processing (NLP) tools. NLP remains promising for oncology research,¹¹ but

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on February 27, 2020 and published at ascopubs.org/journal/cci on May 15, 2020; DOI <https://doi.org/10.1200/CCI.19.00134>

CONTEXT

Key Objective

To demonstrate the utility of an information retrieval system, the Electronic Medical Record Search Engine (EMERSE), in the context of supporting cancer research.

Knowledge Generated

An analysis of audit logs and peer-reviewed publications demonstrated that EMERSE is being used to support cancer research for a broad array of research projects and tasks, ranging from cohort identification to data abstraction for elements that may not be found in a structured form. Users are searching for a wide variety of concepts, including “pharmacologic substance,” “neoplastic process,” and “sign or symptom.”

Relevance

Information retrieval systems such as EMERSE have the potential to be powerful and easy-to-use software tools for supporting cancer research. EMERSE is available at no cost and has been successfully implemented at multiple medical centers, so it is a viable option for sites seeking to provide additional software tools for supporting cancer research.

widespread use remains limited. The quality of NLP results have been mixed, with some acknowledging the complexity and “inherent difficulty of natural language processing in this domain.”^{6(p330-331)} This complexity results from a variety of factors, including understanding temporal relationships, ambiguous abbreviations, and anaphoric references. Other challenges include issues of replicability across algorithms and institutions¹² and the need for large manually annotated data sets for new use cases,¹¹ especially because these systems perform best when tailored to a specific task or domain.¹³ The lack of available experts to architect and deploy NLP systems is also a limiting factor.

To address the immediate needs of the cancer research community, members of which often lack the resources, time, and access to NLP experts, we developed a simpler approach using information retrieval for concept identification in free text. The Electronic Medical Record Search Engine (EMERSE) is a general-purpose term-searching system tailored to the needs of the medical research community to help researchers quickly find information buried in EHR free text. In general, information retrieval is like search engines such as Google that help people find information quickly, but it does not attempt to code the data, the latter of which falls within the domain of NLP. General familiarity with tools such as Google is thus an advantage. EMERSE uses an index of terms coupled with the capacity for query expansion using locally customized or standardized terminologies.

Rather than an example of an artificial intelligence system, EMERSE is more like an augmented intelligence system, wherein the software helps a person perform his or her work more efficiently but does not completely remove that person from the workflow. With EMERSE, the person is needed for the complex task of making sense of nuanced prose, a task that remains formidable for machines.¹⁴ EMERSE has been in use at the University of Michigan for 15 years and has supported a wide variety of clinical

research, including oncology research. EMERSE is being implemented at other academic medical centers. Our report covers details about the system, including metrics based on use logs and publications, an analysis of search terms entered, and ongoing development work supported by the National Cancer Institute Informatics Technology for Cancer Research program.

METHODS

System Description

EMERSE is a Web-based application that provides an easy-to-use interface for either (1) identifying a cohort among all patients in the EHR or identifying concepts within the clinical unstructured notes of an existing defined patient cohort. EMERSE indexes free-text data from EHR notes, with additional metadata related to the notes (eg, date, clinical service, note type). The software is based on Apache Solr (an open-source search engine), but a substantial user interface has been built to provide study management features, visualization of results, and a query expansion feature.

Technical details about EMERSE can be found in a prior publication.¹⁵ EMERSE maintains detailed audit logs for all user sessions. [Figure 1](#) contains several screens from EMERSE showing various general functions of the system. A recently added feature visualizes trends over time based on the search terms of interest ([Fig 2](#)). Although EMERSE is intended to be a self-service tool, system support is expected to be managed centrally by groups such as operational informatics teams. EMERSE is available at no cost, including source code, but sites are required to contact the University of Michigan to obtain the software. Additional details about EMERSE, including documentation and explainer videos, can be found on the EMERSE project Web site.¹⁶

EMERSE is currently in use at three academic medical centers: University of Michigan, University of North Carolina

A

Patients: Temporary Patient List (30 Patients)
 Dates: All Dates: 02/01/2008 through 01/01/2018
 Terms: "checkpoint inhibitor" nivolumab nh1 lymphoma "ejection fraction" fever anorexia cough "gram negative" genetic "urothelial carcinoma" lymphadenectomy "g c" More...
 Overview Training

Overview

Sorted By: Insert Order Ascending

MRN	Patient Name	Main EHR	Pathology	Radiology	Other	Scanned/ PDFs	Comment	Tag
100000022	RICHARDS, TRACY							
100000057	RAMIREZ, SHELLEY							
100000086	GEORGE, LARRY							
100000096	MORRISON, RUBEN							
100000117	CUMMINGS, RONNIE							

B

Patients: Temporary Patient List (30 Patients)
 Dates: All Dates: 02/01/2008 through 01/01/2018
 Terms: "checkpoint inhibitor" nivolumab nh1 lymphoma "ejection fraction" fever anorexia cough "gram negative" genetic "urothelial carcinoma" lymphadenectomy "g c" More...
 Overview Summaries RICHARDS, TRACY 100000022 Patient 1 of 30 Document 3 of 25 Page Top Page Bottom Print Training

...serum concentration of **CEA** was remarkably elevated...
 ...nephroureterectomy and para-aortic **lymphadenectomy**. The histological...
 ...revealed infiltrating **urothelial carcinoma** with positive staining...
 ...staining for **CEA** antibody. The postoperative course...
 ...months after the operation, **CEA** producing infiltrating...
 ...infiltrating **urothelial carcinoma** of the renal pelvis is reported...

Document:

Journal: Urology case reports

Article Title: Granulocyte-Colony Stimulating Factor Producing Infiltrating **Urothelial Carcinoma** of the Left Renal Pelvis: A Case Report.

PMID/DOI: 27818946

Publication Date: 2017-Jan-09

Abstract:

We report a case of granulocyte-colony stimulating factor (**CEA**) producing infiltrating **urothelial carcinoma** of the left renal pelvis. The patient was referred to our hospital for **CEA** and **CEA**. Blood tests showed elevated level of leukocytosis without any infectious diseases. The serum concentration of **CEA** was remarkably elevated. Abdominal computed tomography (CT) revealed a huge mass in the left renal pelvis and para-aortic lymph node enlargement. He was underwent left nephroureterectomy and para-aortic **lymphadenectomy**. The histological examination revealed infiltrating **urothelial carcinoma** with positive staining for **CEA** antibody. The postoperative course was smooth and the leukocyte count became normalized within a week postoperatively. However, multiple lung metastasis and leukocytosis were revealed about 2 months after the operation. **CEA** producing infiltrating **urothelial carcinoma** of the renal pelvis is reported to have a significantly poor prognosis, so it is very important to monitor closely after the operation.

C

Patients: Temporary Patient List (30 Patients)
 Dates: All Dates: 02/01/2008 through 01/01/2018
 Terms: "checkpoint inhibitor" nivolumab nh1 lymphoma "ejection fraction" fever anorexia cough "gram negative" genetic "urothelial carcinoma" lymphadenectomy "g c" More...
 Overview Quick Terms Term Bundles Advanced Terms Training

Upload Terms

Search Options

Terms to include

Click on the term to edit

"checkpoint inhibitor" Synonyms

nivolumab Synonyms

nh1 Synonyms

lymphoma Synonyms

"ejection fraction" Synonyms

fever Synonyms

anorexia Synonyms

cough Synonyms

"gram negative" Synonyms

genetic Synonyms

Click individual terms to highlight or de-highlight

Synonyms (12)

936558 anti-PD-1 human monoclonal antibody MDX-1106 BMS-936558 BMS936558 MDX MDX 1106 MDX1106 nivo ONO

ONO-4538 ONO4538 Opdivo

Spelling Alternatives (6)

nivolumab nivolumab nivolumab nivolumab nivolumab optivo

Highlight All De-Highlight All Add Highlighted Terms




FIG 2. Examples of the graphs available within the Electronic Medical Record Search Engine (EMERSE) trends feature. The graphs have been redrawn from the original screenshots for clarity within this publication. The graphs show the number of distinct patients per year with at least one note in the electronic health record mentioning the search term of interest, which can be useful for looking at patient trends over time. (A) Rapid increase in the mention of checkpoint inhibitor. (B) Gradual decrease in the mention of radical mastectomy, ignoring notes that mention modified radical mastectomy (query: “radical mastectomy” NOT “modified radical mastectomy”). Note that 2019 data are through mid December.

at Chapel Hill, and University of Cincinnati (Table 1). Other sites are currently at various stages in their implementation, including Case Western Reserve University (CWRU)/University Hospitals of Cleveland, Columbia University, University of Kentucky, University of Utah, and University of California San Francisco. CWRU has implemented a version of EMERSE using data extracted from the MIMIC-III project¹⁷ and plans to use EMERSE in a pilot program for training medical students about research software and as part of its health informatics training program.

Publication Data

Peer-reviewed publications using EMERSE were identified via manual searches for “EMERSE” or “electronic medical record search engine” in both PubMed and Google Scholar. Searches were conducted between August and September 2019. Each article identified was reviewed to confirm EMERSE use. To identify additional peer-reviewed publications without mention or citation of EMERSE, all principal investigators at the University of Michigan who had used EMERSE for research within the prior 5-year period ($n = 600$) were sent an e-mail in July/August 2019 to inquire about the use of EMERSE for their work and what publications arose from that use. The e-mail contained personalized audit logs to remind them about the

use. A follow-up e-mail to nonresponders was sent in early September 2019. For all articles identified, the titles and abstracts were read to determine if they were cancer related.

To characterize how EMERSE was used to support various research initiatives, 47 recent cancer-related peer-reviewed publications published within the last 2 years were reviewed. Among these, 11 were summarized with respect to their descriptions of how EMERSE was used. These 11 articles were selected to showcase a diversity of use cases, were from a variety of research teams from different disciplines, and had enough details described in their methods sections to understand the contribution of EMERSE.

Audit Log Analysis

Use logs were extracted to characterize the total number of users and the number of EMERSE logins over the past 5 years (September 2014 through August 2019; shorter timeframes for the two sites that recently adopted the system). The search terms (ie, search queries) entered within this timeframe were also extracted. The NLP tool MetaMap¹⁸ was used to process the search terms from two of the sites (University of Michigan and University of Cincinnati; University of North Carolina did not provide its terms). For this analysis, the “-a -N” flags were used. The

FIG 1. Screenshots of some basic features within Electronic Medical Record Search Engine (EMERSE). (A) Overview in which each row represents a patient in a list, and columns represent document sources. The colors in each cell represent terms for each patient and source that appear in that patient's documents. The colors are associated with the colors of the highlighted search terms, shown across the navigation panel at the top. (B) Example of a specific note (in this case, a PubMed abstract; names and medical record numbers are fake), with the terms still highlighted in the note. (C) Term expansion feature, with additional synonyms for nivolumab shown.

TABLE 1. Description of the Three Sites Currently Live With EMERSE

Institution	Go-Live Date	No. of Patients (millions)	No. of Documents (millions)	No. of Users	No. of Logins
University of Michigan	Dec 2005	2.5	170	3,308 ^a	97,632 ^a
University of North Carolina at Chapel Hill	Nov 2017	2.6	90	163 ^b	1,957 ^b
University of Cincinnati	Feb 2019	0.9	27	24 ^b	550 ^b
Overall	NA	6.0	287	3,495	100,139

Abbreviations: EMERSE, Electronic Medical Record Search Engine; NA, not applicable.

^aLast 5 years.

^bSince go-live date.

“-a” flag enables the use of variants of acronyms and abbreviations, and the “-N” flag modifies how the output is displayed. Prior studies have shown that MetaMap can perform comparably to other NLP tools, such as cTAKES.¹⁹

MetaMap processed each search term to determine if MetaMap could map the query to a concept unique identifier (CUI) within the Unified Medical Language System (UMLS)²⁰ and, if the concept could be identified, to what semantic type it belonged. Because MetaMap outputs a list of potential CUI candidates, only the top-scoring candidate was selected. For ties among top-scoring candidates, only the first was selected. The results across the two sites were merged, and the relative frequencies of the top 20 most common UMLS semantic types were visualized using RAWGraphs.²¹

RESULTS

A total of 222 peer-reviewed publications were identified through manual searches using PubMed and Google Scholar through September 19, 2019. For the e-mail survey that was conducted to gain additional data about publications, 337 (56.2%) of the 600 principal investigators responded, revealing an additional 105 peer-reviewed publications that did not cite or mention EMERSE, bringing the total number of publications to 326. Of the 326 publications, 105 (32.2%) were oncology related. An additional 285 studies were still in progress, with potential publications coming at a later date. The current list of known peer-reviewed publications can be found on the EMERSE project Web site.¹⁶ Summaries of how EMERSE was used for 11 selected oncology-related

TABLE 2. Examples of Cancer-Related Publications Supported With Use of EMERSE

Publication	Description of EMERSE Use	Site of EMERSE Use
Ernecoff ²⁵	To develop EHR phenotypes for identifying patients with late-stage solid tumor cancers	University of North Carolina at Chapel Hill
Zhang ³⁰	Case identification for patients with a malignant Brenner tumor (no specific ICD-10 code exists for this diagnosis)	University of North Carolina at Chapel Hill
Tsao ³¹	Data abstraction for disease and treatment characteristics, performance status, and comorbid conditions (eg, hypertension, diabetes mellitus, congestive heart failure, cardiac arrhythmias)	University of Michigan
Siontis ³²	Cohort identification: identify patients with a diagnosis of primary cardiac sarcoma	University of Michigan
Lazo de la Vega ³³	Cohort identification: patients with low-grade endometrioid endometrial carcinoma, FIGO grade I/II at time of hysterectomy	University of Michigan
Shankar ³⁴	Case identification using lymph node pathology	University of Michigan
Hertz ³⁵	Screening for patients with actionable phenotypes to determine if they received a relevant drug, using generic and brand drug names	University of Michigan
Morag ³⁶	Cohort identification of pathology-proven cases of well-differentiated liposarcomas with myxoid stroma	University of Michigan
Aslam ³⁷	To review abdominopelvic and chest CT imaging reports for identifying the presence of metastatic disease and the sites of initial tumor and metastases when present	University of Michigan
Chappell ³⁸	Data abstraction for multiple transplantation-related variables, as well as disease and patient-specific data	University of Michigan
Manohar ³⁹	Data abstraction for demographic, clinical, staging, and pathologic data, among others; review of PET scan results	University of Michigan

NOTE. References are shown with a brief description of how EMERSE was used based on the methods section of the articles.

Abbreviations: CT, computed tomography; EMERSE, Electronic Medical Record Search Engine; FIGO, International Federation of Obstetrics and Gynecology; ICD-10, International Classification of Diseases, 10th edition; PET, positron emission tomography.

articles are provided in Table 2. The use of EMERSE varied from cohort identification to various types of data abstraction.

The audit logs revealed substantial use of EMERSE for cancer-related work that did not acknowledge EMERSE use within publications. This included multisite clinical trials where EMERSE was used at a single site (University of Michigan). These publications could be identified via unique data, such as National Clinical Trial numbers, which were sometimes mentioned in the publications. Examples include one study that used EMERSE for 31 sessions, with a total session time of 13 hours (ClinicalTrials.gov identifier: [NCT01865747](#)),²² another that used EMERSE for 58 sessions and 26 hours (ClinicalTrials.gov identifier: [NCT01576172](#)),²³ and a third that used EMERSE for 398 user sessions and 166 hours (ClinicalTrials.gov identifier: [NCT01633372](#)).²⁴

Other oncology-related research initiatives have used EMERSE, even though it is not possible to link the use back to specific studies. For example, the Michigan Medicine Oncology Clinical Trials Support Unit has an umbrella institutional review board application for which it accesses EMERSE but does not link use to a specific study. That unit logged into EMERSE 917 times for 388 hours of use on the system between December 2014 and July 2019. Additionally, the Bone Marrow Transplant research group uses EMERSE for tracking long-term outcomes and used EMERSE for 2,452 sessions and 1,106 hours between July 2014 and July 2019. The high number of logins per study is common for research that involves frequent patient monitoring or identification of adverse events. Additional use statistics are listed in Table 1.

Details about the analysis of search terms using MetaMap are listed in Table 3. A large number of terms (University of Michigan, 34.1%; University of Cincinnati, 55.9%) did not map to any CUI using MetaMap. Many of these non-mapping terms were misspellings (eg, “fludaribine,” “ifosphomide,” “pegasparaganase,” “tamoxafen”). However, of the terms that did not map from the University of Michigan data set, 2,342 (9.0%) were numbers in various forms representing medical record numbers, dates, international classification of disease (ICD) codes, and even pathology slide identifiers. In the University of Cincinnati data set 1,975 (68.6%) of the terms that did not map were numbers. The relative frequency of the 20 most common

semantic types for the search terms is shown in Figure 3. “Disease or syndrome” was the most frequent semantic type (11.5%), followed by “pharmacologic substance” (10.0%).

DISCUSSION

As shown by the audit logs, and as evidenced by numerous peer-reviewed publications (> 100 oncology related), EMERSE has proven to be a useful tool for supporting cancer research. Furthermore, EMERSE has been successfully deployed at three academic medical centers to date, including the University of North Carolina, with additional centers in process, leading to multiple peer-reviewed publications.²⁵

Through several rounds of implementation work with other sites (several are still under way), we have learned a great deal about the complexities of enterprise-wide software implementation. We describe a few of the most important insights, provided as guidance for others who might be interested in implementing EMERSE or other centrally managed research tools.

Environments at each site are highly variable, including servers, storage, access to EHR documents, formats of these documents, and regulatory requirements. Although there is no cost per se for the software, the resources needed for implementation are not free. Competing priorities, institutional review board requirements, small teams, security reviews, and the need to obtain buy-in from leadership can delay implementation for months. There is no single solution to overcoming these challenges, but we have made efforts to reduce the burden on implementing sites, including providing installation and setup documentation, training materials for end users, and a messaging forum for technical teams.

Because EMERSE is meant to be user facing, preserving the original document formatting helps users understand the data in the notes. Modern EHRs, such as Epic, allow for documentation using rich text formatting, in which notes can be made with tables, line breaks, and other formatting (eg, bold-face text). However, the Epic analytics database, Clarity, almost universally stores a version of the notes stripped of all formatting. The University of North Carolina at Chapel Hill has avoided using Clarity and is using the live production database, Chronicles, instead.

TABLE 3. Results of MetaMap Search Terms Mapping and Total No. of Distinct Terms Entered at Each Site

Institution	Distinct Search Terms	Terms That Did Not Map	Unique CUIs Mapped	Unique Semantic Types ^a
University of Michigan	76,540	26,098 (34.1%)	18,184	120
University of North Carolina at Chapel Hill	2,855	NA ^b	NA ^b	NA ^b
University of Cincinnati	5,151	2,881 (55.9%)	1,281	88

Abbreviations: CUI, concept unique identifier; NA, not applicable.

^aOf 127 possible semantic types. The full list of semantic types can be found online.⁴⁰

^bRaw data not available for analysis.




FIG 3. Tree map showing the relative frequency of the top 20 most common semantic types based on search terms entered, with data combined from the University of Michigan and University of Cincinnati. These 20 semantic types together represent 74.3% of all of the concept unique identifiers identified by applying MetaMap to the search terms.

The University of Utah, one of our partners, is working on a solution based on application program interfaces compliant with the Health Level Seven Fast Healthcare Interoperability Resources²⁶ standard that should solve this challenge by extracting formatted notes in bulk. This approach is aligned with priorities of the US National Institutes of Health to “explore the use of the Fast Healthcare Interoperability Resources (FHIR) standard to capture, integrate, and exchange clinical data for research purposes and to enhance capabilities to share research data.”^{27(p1)} Other sites, such as University of Cincinnati, have used simple logic and regular expressions to rebuild functional formatting in the notes.

Contrary to when EMERSE was first developed and deployed, security considerations are becoming a top priority, as they are for any software that contains protected health information within a medical center. This focus on security requires substantial, ongoing resources for conducting repeated scans for vulnerabilities that exist in the underlying open-source components, as well as in the system configuration, code reviews, penetration testing, and other measures. This work adds to the development costs but is a necessary component that other sites are requiring before considering a deployment. The importance of software security, as well as local institutional policies, should not be underestimated.

Finally, demonstrating the value, effectiveness, and return on investment of software such as EMERSE remains challenging, especially if one considers peer-reviewed publications to be the gold standard of evidence. As demonstrated by the number of times the tool was used but never cited or mentioned, referencing software tools are not a top priority for many in the research community. However, this type of attribution is important to ensure future funding for software development teams, which can be expensive.

For the analysis of semantic types, it is worth noting that only a few of the semantic types identified are for data typically found in the structured section of EHRs (eg, diseases, pharmaceutical substances). Many of the other concepts are likely to be found only in the free-text notes. Furthermore, many of the terms entered by users were not mappable by the popular NLP tool MetaMap. This could be because of limitations of current NLP tools or because users of EMERSE are searching for concepts that do not have a matching CUI or semantic type within UMLS.

The performance of MetaMap in our case likely could have been improved by adding an additional preprocessing step wherein incorrectly spelled terms would be mapped back to their correct spellings. Even though signs and symptoms are almost exclusively noted in the narrative portion of the medical record, these did not represent the most frequent semantic type. However, this may be because our analysis

was performed on a unique list of terms in the search logs, and there may be far fewer signs and symptoms than there are disease or drug names.

Additional work under way involves securely networking sites for obfuscated counts. This feature will be similar to other cohort discovery networks currently based on structured data, such as i2b2 ACT²⁸ and PCORnet,²⁹ but the novelty with the EMERSE-based network is the focus on free-text notes. This should be useful for finding rare cancer cases where structured data are not specific enough. For example, there is no specific code in the ICD (version 10) for endometrial stromal sarcoma, because the parent code C54.1 represents multiple types of endometrial neoplasms.

It is important to point out that EMERSE is not meant to be a replacement for NLP systems, and NLP will be a preferable option in certain use cases. For relatively small numbers of patients (eg, thousands) and where accuracy is important enough to warrant human review, EMERSE may be the tool of

choice. In other situations, such as automatically coding data across hundreds of thousands or millions of patients, NLP may be a preferable option. There is no one-size-fits-all solution, and multiple tools can benefit the research enterprise.

In conclusion, EMERSE can be a valuable tool to support cancer research as well as other clinical domains. This is a simple-to-operate, self-service tool that is powerful, scalable, and generalizable across use cases, allowing for teams from various fields to increase their productivity and gain access to accurate patient data that normally would have required a manual approach for identification. In addition, it has many data security features. Successful implementation at other locations has demonstrated that EMERSE can be deployed and used outside its original site. Groups interested in adopting EMERSE can contact the EMERSE team at the University of Michigan for a working virtual machine for testing, demonstrations, advice, and other details.

AFFILIATIONS

¹Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI

²Case Western Reserve University School of Medicine, Cleveland, OH

³University Hospitals of Cleveland, Cleveland, OH

⁴Cleveland Institute for Computational Biology, Cleveland, OH

⁵Department of Biomedical Informatics, University of Utah, Salt Lake City, UT

⁶Markey Cancer Center, UK HealthCare, Lexington, KY

⁷Division of Biomedical Informatics, University of Kentucky, Lexington, KY

⁸Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA

⁹Department of Biomedical Informatics, University of Cincinnati College of Medicine, Cincinnati, OH

¹⁰Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

¹¹North Carolina Translational and Clinical Sciences Institute, University of North Carolina School of Medicine, Chapel Hill, NC

¹²Department of Informatics, University of California, Irvine, CA

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CORRESPONDING AUTHOR

David A. Hanauer, 100-134 NCRC, 2800 Plymouth Rd, Ann Arbor, MI 48109; e-mail: hanauer@umich.edu.

SUPPORT

Supported in part by National Cancer Institute (NCI) Informatics Technology for Cancer Research, National Institutes of Health (NIH), Grant No. 1U24CA204863-01A1 and Clinical and Translational Science Award (CTSA)-supported Michigan Institute for Clinical and Translational Research Grant No. UL1TR002240; by the Cleveland Institute for Computational Biology and the Clinical and Translational Science Collaborative (CTSC) of Cleveland, funded by NIH National Center for Advancing Translational Science (NCATS) CTSA Grant No. UL1TR002548; by the North Carolina Translational and Clinical Sciences Institute, funded by NIH NCATS Grant No. UL1TR002489; and by the Markey Cancer Center Cancer Research Informatics Shared

Resource Facility through NCI Cancer Center Support Grant No. P30CA177557.

AUTHOR CONTRIBUTIONS

Conception and design: David A. Hanauer, Mark F. Beno, Daniel Harris, Benjamin May, Kai Zheng

Administrative support: Eric Meeks

Provision of study material or patients: Eric B. Durbin, Oksana Gologorskaya

Collection and assembly of data: David A. Hanauer, Eric B. Durbin, Oksana Gologorskaya, Brett Harnett, Eric Meeks, Emily Pfaff

Data analysis and interpretation: David A. Hanauer, Jill S. Barnholtz-Sloan, Guilherme Del Fiol, Eric B. Durbin, Kensaku Kawamoto, Eric Meeks, Janie Weiss

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

David A. Hanauer

Patents, Royalties, Other Intellectual Property: Creator of a large database of clinical synonyms that can be used for query expansion, licensed by the University of Michigan Office of Technology Transfer and available for academic and nonacademic use (currently only licensed for academic use)

Kensaku Kawamoto**Honoraria:** Hitachi, Premier**Consulting or Advisory Role:** US Office of the National Coordinator for Health Information Technology via Security Risk Solutions and ESAC, McKesson InterQual, Klesis Healthcare**Research Funding:** Hitachi (Inst)**Patents, Royalties, Other Intellectual Property:** Internal (University of Utah) invention disclosures related to our work in health information technology, primarily for copyright protection (no royalty arrangements at present or in the past 2 years)**Travel, Accommodations, Expenses:** Hitachi**Other Relationship:** RTI International, University of Washington, University of California at San Francisco, American Association of Medical Colleges, Mayo Clinic, Health Level Seven International**Eric Meeks****Stock and Other Ownership Interests:** WestPac Wealth Partners

No other potential conflicts of interest were reported.

REFERENCES

1. Murdoch TB, Detsky AS: The inevitable application of big data to health care. *JAMA* 309:1351-1352, 2013
2. Polnaszek B, Gilmore-Bykovskiy A, Hovanes M, et al: Overcoming the challenges of unstructured data in multisite, electronic medical record-based abstraction. *Med Care* 54:e65-e72, 2016
3. Kharrazi H, Anzaldi LJ, Hernandez L, et al: The value of unstructured electronic health record data in geriatric syndrome case identification. *J Am Geriatr Soc* 66:1499-1507, 2018
4. Hernandez-Boussard T, Tamang S, Blayney D, et al: New paradigms for patient-centered outcomes research in electronic medical records: An example of detecting urinary incontinence following prostatectomy. *EGEMS (Wash DC)* 4:1231, 2016
5. Raghavan P, Chen JL, Fosler-Lussier E, et al: How essential are unstructured clinical narratives and information fusion to clinical trial recruitment? *AMIA Jt Summits Transl Sci Proc* 2014:218-223, 2014
6. Sholle E, Krichevsky S, Scandura J, et al: Lessons learned in the development of a computable phenotype for response in myeloproliferative neoplasms. *IEEE Int Conf Healthc Inform* 2018:328-331, 2018
7. Chang L, Frame D, Braun T, et al: Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. *Biol Blood Marrow Transplant* 20:1407-1417, 2014
8. Birman-Deych E, Waterman AD, Yan Y, et al: Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. *Med Care* 43:480-485, 2005
9. Walsh KE, Marsolo KA, Davis C, et al: Accuracy of the medication list in the electronic health record-implications for care, research, and improvement. *J Am Med Inform Assoc* 25:909-912, 2018
10. Warner JL, Levy MA, Neuss MN, et al: ReCAP: Feasibility and accuracy of extracting cancer stage information from narrative electronic health record data. *J Oncol Pract* 12:157-158, e169-e7, 2016
11. Savova GK, Danciu I, Alamudun F, et al: Use of natural language processing to extract clinical cancer phenotypes from electronic medical records. *Cancer Res* 79:5463-5470, 2019
12. Carrell DS, Schoen RE, Leffler DA, et al: Challenges in adapting existing clinical natural language processing systems to multiple, diverse health care settings. *J Am Med Inform Assoc* 24:986-991, 2017
13. Kreimeyer K, Foster M, Pandey A, et al: Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review. *J Biomed Inform* 73:14-29, 2017
14. Gorski D: IBM Watson: Not living up to hype as a tool to fight cancer? <https://scienceblogs.com/insolence/2017/09/18/ibm-watson-not-living-up-to-hype-as-a-tool-to-fight-cancer>
15. Hanauer DA, Mei Q, Law J, et al: Supporting information retrieval from electronic health records: A report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). *J Biomed Inform* 55:290-300, 2015
16. EMERSE: Electronic Medical Record Search Engine. <http://project-emerse.org>
17. Johnson AEW, Pollard TJ, Shen L, et al: MIMIC-III, a freely accessible critical care database. *Sci Data* 3:160035, 2016
18. MetaMap: A tool for recognizing UMLS concepts in text. <https://metamap.nlm.nih.gov>
19. Reátegui R, Ratté S: Comparison of MetaMap and cTAKES for entity extraction in clinical notes. *BMC Med Inform Decis Mak* 18:74, 2018 (suppl 3)
20. Wu ST, Liu H, Li D, et al: Unified Medical Language System term occurrences in clinical notes: A large-scale corpus analysis. *J Am Med Inform Assoc* 19(e1): e149-e156, 2012
21. Mauri M, Elli T, Caviglia G, et al: RAWGraphs: A visualisation platform to create open outputs. Presented at the 12 Biannual Conference of the Italian SIGCHI Chapter, Cagliari, Italy, September 18-20, 2017
22. Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 373:1814-1823, 2015
23. Hussain M, Dignault-Newton S, Twardowski PW, et al: Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. *J Clin Oncol* 36:991-999, 2018
24. Mascarenhas JO, Talpaz M, Gupta V, et al: Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. *Haematologica* 102:327-335, 2017
25. Ernecoff NC, Wessell KL, Hanson LC, et al: Electronic health record phenotypes for identifying patients with late-stage disease: A method for research and clinical application. *J Gen Intern Med* 34:2818-2823, 2019
26. Bender D, Sartipi K: HL7 FHIR: An Agile and RESTful approach to healthcare information exchange. Presented at the 26 IEEE International Symposium on Computer-Based Medical Systems, Porto, Portugal, June 20-22, 2013
27. National Institutes of Health Office of Data Science Strategy: Fast Healthcare Interoperability Resources (FHIR) standard. <https://datascience.nih.gov/foa/fast-healthcare-interoperability-resources-fhir-standard>
28. Visweswaran S, Becich MJ, D'Itri VS, et al: Accrual to Clinical Trials (ACT): A Clinical and Translational Science Award Consortium Network. *JAMIA Open* 1:147-152, 2018
29. Fleurence RL, Curtis LH, Califf RM, et al: Launching PCORnet, a national patient-centered clinical research network. *J Am Med Inform Assoc* 21:578-582, 2014
30. Zhang Y, Staley SA, Tucker K, et al: Malignant Brenner tumor of the ovary: Case series and review of treatment strategies. *Gynecol Oncol Rep* 28:29-32, 2019

31. Tsao PA, Estes JP, Griggs JJ, et al: Cardiovascular and metabolic toxicity of abiraterone in castration-resistant prostate cancer: Post-marketing experience. *Clin Genitourin Cancer* 17:e592-e601, 2019
 32. Siontis BL, Zhao L, Leja M, et al: Primary cardiac sarcoma: A rare, aggressive malignancy with a high propensity for brain metastases. *Sarcoma* 2019:1960593, 2019
 33. Lazo de la Vega L, Samaha MC, Hu K, et al: Multiclonality and marked branched evolution of low-grade endometrioid endometrial carcinoma. *Mol Cancer Res* 17:731-740, 2019
 34. Shankar PR, Barkmeier D, Hadjiiski L, et al: A pictorial review of bladder cancer nodal metastases. *Transl Androl Urol* 7:804-813, 2018
 35. Hertz DL, Glatz A, Pasternak AL, et al: Integration of germline pharmacogenetics into a tumor sequencing program. *JCO Precis Oncol* [10.1200/PO.18.00011](https://doi.org/10.1200/PO.18.00011)
 36. Morag Y, Yablon C, Brigido MK, et al: Imaging appearance of well-differentiated liposarcomas with myxoid stroma. *Skeletal Radiol* 47:1371-1382, 2018
 37. Aslam A, Mendiratta-Lala M, Curci ME, et al: Role of pelvic CT during surveillance of patients with resected biliary tract cancer. *Abdom Radiol (NY)* 45:116-122, 2020
 38. Chappell G, Geer M, Gatz E, et al: Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. *Bone Marrow Transplant* 54:1518-1520, 2019
 39. Manohar PM, Beesley LJ, Bellile EL, et al: Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. *Clin Nucl Med* 43:641-647, 2018
 40. MetaMap: List of semantic types. https://metamap.nlm.nih.gov/Docs/SemanticTypes_2018AB.txt
-